We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We may also share information about your use of our site with our social media, advertising and analytics partners. Read more about our Privacy Policy.

I got it!

18th Pharmacovigilance 2019

Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management

18th Pharmacovigilance 2019

27th & 28th February 2019, Pestana Chelsea Bridge Hotel, London, UK

18th Annual Pharmacovigilance 2019 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the ; The entire program will cover the detection, analysis and prevention of adverse drug reactions. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organizations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pharmacovigilance requirements, and to improve their organization’s compliance with pharmacovigilance requirements. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.


  • Bronze Sponsor: BROOKWOOD


  • JACKIE ROBERTS, Executive Director Regulatory, Pharmacovigilance and Medical / QPPV, Accord Healthcare
  • JABEEN AHMAD, Regional PV Director, EEMEA, Abbvie
  • SUSAN WELSH, Chief Safety Officer, CSL Behring (USA)
  • RICARDA TIEMEYER, Head of Drug Safety & PoC Medical Information, Roche
  • PAOLO VOLTOLINA, Associate Director Regulatory Affairs, CSL Behring
  • MIROSLAVA NOVAKOVA, Medical Advisor, Sanofi Pasteur (Slovak Republic)
  • YUUNG YUUNG YAP, Senior International Regulatory Counsel, EU and International Regulatory Law, Pfizer
  • DAVID JEFFERYS, Sr. VP Regulatory, Eisai
  • TANJA PETERS, Global Head of PV Intelligence, Deputy EU QPPV, Boehringer Ingelheim
  • JOHN SOLOMON, Head of Pharmacovigilance - UK & Ireland, Sanofi
  • SUMIT MUNJAL, Global Director, Pharmacovigilance & EU Region Medical Advisor - Lead Oncology Portfolio, Takeda Pharmaceuticals
  • MICHAEL BEAN, Senior Director, Regulatory Compliance R&D, Johnson & Johnson
  • STEINAR MADSEN, Medical Director, Norweigen Medicines Agency
  • PAUL WANG, Director, Safety Science, Kite Pharma (USA)
  • DORIS STENVER, Chief Medical Officer, Member of the Pharmacovigilance Risk Assessment Committee (PRAC), Danish Medicines Agency
  • ALEJANDRA PADOVANI, Safety Scientist, Roche
  • SABINE POLTERMANN, Head Scientific Product Information, Novartis
  • HEINZ WEIDENTHALER, Director Pharmacovigilance, QPPV, Bavarian Nordic
  • MIRCEA CIUCA, Global Head Medical & Clinical Drug Safety, Vifor Pharma
  • FRANCK SCHWARTZ, QA Global Inspection, Intelligence Lead - Compliance and Regulatory Affairs, Novartis
  • ALINA TUDOR, Associate Director, Senior PV Physician/Deputy EUQPPV, Norgine
  • RAJ BHOGAL, Safety & International Director, Regulatory Inspections, R&D QA&C, Shire Pharmaceuticals

Plus many more


  • Brexit Implications for the UK Pharmaceutical (pharmacovigilance) Industry
  • What would 'no deal' mean for medicine?
  • New Technologies in Pharmacovigilance (AI/ Machine Learning, IoT)
  • Quality, Safety and Signal Detection - Future of 2020 
  • PV Audit & Inspections – Knowing what is to be done
  • Drug safety work in the pre-clinical/clinical transition and early clinical development phase
  • Pharmacovigilance in 2020 - future horizons and efficiencies
  • Updates towards of legislation, policies, systems, technology, communication strategies and best practice in PV
  • Possible effects of Brexit on Pharmacovigilance
  • Benefit/Risk ratio: the common denominator
  • Market analysis – What is our current stand? – Moving towards the new successful PV era
  • PV – Risk Management and Planning
  • Risk management in the lifecycle of a drug
  • Examining developments in GVP measures and status of the new Module VI
  • Improving in signal management and their implications
  • Latest updates and hot topics relating to the role of the QPPV
  • Challenges and Opportunities to optimize the overall PV ecosystem for maximum benefit
  • Quality, Safety and Signal Detection - Future of 2020 
  • Medical devices – Increasing safety perspective
  • Case studies from various countries on the PV frameworks around the world
  • Good Clinical Practices and Good Pharmacovigilance practices
  • Proper communication - Sponsor – Site – CRO & Patients
  • Patient centric approach to help improve patient safety
  • Outsourcing activities - How to set it right?
  • How to involve patients better to develop drugs
  • The developing regulatory framework in advanced and developing markets – EU, USA & ROW
  • Accelerating new medicine introduction in developing world & overcoming challenges
  • Be part of a major networking opportunity


CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing


Email: kavitha@  or TEL: +44 2036120886

Sponsor, Exhibition Stall (Booth) and a paid Speaker Slots are also available

We also have some sponsorship opportunities available for the event, which gives you an opportunity to sponsor/speak/exhibit, and create brand awareness. In addition, the networking opportunities in focused and relevant industry gathering provide the personal contact necessary for business development efforts.


Email: kavitha@  or TEL: +44 2036120886

  • Introductory Offer (3 delegate places for the price of 2) - A huge saving discount and only Limited seats left.
  • Early Bird Discount (Ends 17th January 2019): Conference Delegate Pass (£950 + VAT per delegate)
  • Standard Registration (From 19th January 2019): Conference Delegate Pass (£1150 + VAT per delegate)

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference.



27 Feb 2019 @ 09:00 am

28 Feb 2019 @ 05:30 pm

Duration: 1 days, 8 hours


Pestana Chelsea Bridge Hotel

354 Queenstown Rd, London SW8 4AE, UK

SW8 4AE London

United Kingdom

Organised by

VIrtue Insight

Premium Events in Biotechnology

Recent Publications in Biotechnology

Recent Videos in Biotechnology

Recent News in Biotechnology

Happening NOW: Slovak visiting scientists process ⁦samples from the Joint Danube Survey 2019 ⁦@EU_ScienceHub⁩. Prou… https://t.co/MAgB3ASZug

@EU_ScienceHub - 16 Jul 2019 14:27

The quality of our health & the quality of the environment in which we live are closely linked The #H2020… https://t.co/UDD8Wxwdg9

@EU_H2020 - 16 Jul 2019 12:22

An #EU-backed loan helped Swedish

@EU_H2020 - 16 Jul 2019 10:34

Recent Speakers in Biotechnology

Premium EventsLearn more ..